Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.
Roland Chen, MD
Advertisement
Roland Chen, MD, is the senior vice president of drug development for immunology and cardiovascular at Bristol Myers Squibb.
Articles by Roland Chen, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata
5
